Celsion (CLSN) Reports Publication of Thermodox Phase I Clinical Study Results in the Lancet Oncology
Tweet Send to a Friend
Celsion Corporation (NASDAQ: CLSN) today announced that results from a Phase I trial of ThermoDox® were published in the peer-reviewed ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
